ArticleBMC cancer2026
Integrating network pharmacology and experimental validation to elucidate the mechanism by which 2-Dihydroailanthone induces HCT116 cell death through suppressing autophagy via the AMPK/mTOR pathway.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
BACKGROUND AND
objectiveColorectal cancer (CRC) is a highly prevalent and challenging malignancy worldwide, with chemotherapy resistance and tumor recurrence posing significant clinical hurdles. Previous studies have indicated that activation of protective autophagy under tumor microenvironment stress plays a key role in cancer cell survival and drug resistance. Consequently, inhibiting protective autophagy has emerged as a promising anti-CRC strategy. This study aims to investigate whether 2-Dihydroailanthone, an active constituent isolated from the bark of Ailanthus altissima (a traditional Chinese medicinal plant), induces CRC cell death by suppressing protective autophagy and to elucidate the underlying molecular mechanisms.
methodsNetwork pharmacology was initially employed to predict the potential targets of 2-Dihydroailanthone and to perform pathway enrichment analyses. Molecular docking evaluated its binding interactions with the core targets AMPK and mTOR. Human CRC HCT116 cells were used as an experimental model to assess cell viability, migration, and apoptosis via CCK-8 assay, wound healing assay, and flow cytometry, respectively. Ultrastructural changes and autophagosome formation were examined through transmission electron microscopy (TEM). Protein expression of AMPK/mTOR pathway components and autophagy markers (LC3B-II and p62) were analyzed by Western blotting. Pharmacological gain- and loss-of-function experiments employed the AMPK activator GSK621 and the inhibitor Compound C to validate pathway involvement.
resultsNetwork pharmacology revealed significant enrichment of 2-Dihydroailanthone’s potential targets in autophagy- and AMPK/mTOR-related pathways. Molecular docking demonstrated high-affinity binding of 2-Dihydroailanthone to the active sites of AMPK and mTOR. Functional assays showed that 2-Dihydroailanthone suppressed HCT116 cell viability and migration in a dose-dependent manner and notably induced apoptosis. TEM analyses revealed mitochondrial damage accompanied by reduced autophagosome formation. Correspondingly, Western blot analyses showed decreased LC3B-II levels and accumulation of p62, indicating suppressed autophagic flux. Mechanistically, 2-Dihydroailanthone inhibited AMPK phosphorylation and activated mTOR signaling. These effects were partially reversed by GSK621 and enhanced synergistically by Compound C.
conclusionThis study demonstrates, for the first time, that 2-Dihydroailanthone suppresses protective autophagy and induces apoptosis in HCT116 cells by modulating the AMPK/mTOR pathway. These findings suggest the potential of 2-Dihydroailanthone as a candidate anti-CRC agent and provide new molecular insights for CRC therapies targeting autophagy regulation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.